Stage IIIB Skin Melanoma Completed Phase 1 Trials for Nivolumab (DB09035)

IndicationStatusPhase
DBCOND0029534 (Stage IIIB Skin Melanoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03229278Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or LymphomaTreatment